EIF2AK2 and melanoma: Indeed, the combination of anti-PD-L1 antibody with IFN treatment of BRAFV600E PTEN-/- melanoma cells was shown to activate NOD-like receptor protein 3 (NLRP3) through protein kinase R (PKR) binding to regulate the inflammasome (Table 1).